Professor John Hayball
Chief Scientific Officer
Prof. John Hayball heads the Experimental Therapeutics Laboratory at the University of South Australia where Sementis conducts and coordinates all their research and development activities.
He is an immunologist and organic chemist, trained in California’s biotech industry and at Imperial College London. His fundamental interest is in translating novel immunotherapeutics to counter emerging infectious disease threats, to re-educate the immune system in allergic disease, and to harness the immune system to treat and prevent cancer, which underpins his contributions to the company’s research and development programs. In partnership with Sementis Ltd, his team at the Experimental Therapeutics Laboratory at the University of South Australia have been instrumental in pioneering the SCV platform technology. He has an intimate knowledge of the design and construction of SCV-based vaccines and evaluation of their performance in complex preclinical disease models.
He also oversees the clinical development of SCV-based vaccines in collaboration with contracted CROs, and clinical and regulatory partners. His extensive clinical translational and regulatory experience includes consulting to biotech and pharma companies, and expert regulatory advice to state, federal and international government biopharmaceutical advisory committees. John was appointed as Chief Scientific Officer of Sementis Ltd in 2020 and retains a Professorial appointment at UniSA.